https://www.selleckchem.com/products/CX-3543.html
Within the study cohort, 16% of patients were treated with originator infliximab, 42% with infliximab-dyyb, and 2% with infliximab-abda. The remaining 41% of patients received at least 2 infliximab products during the study period, primarily infliximab-dyyb and infliximab-abda. Approximately 54% and 42% of infusions encounters included premedication and immunomodulator use. Within the 377 infusion encounters, no infusion reactions were noted. Rapid infusion of infliximab biosimilars (including infliximab-abda) and in patients who have s
Like
Comment
Share
